Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06271538
Other study ID # EP-USM-122023-001
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date May 31, 2024
Est. completion date March 30, 2025

Study information

Verified date April 2024
Source EP Plus Group Sdn Bhd
Contact Jonathan Khor
Phone +60122888024
Email jonathankhor@epplusgroup.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this randomized, double-blind, placebo-controlled study is to evaluate the effectiveness of Skal Pro in alleviating symptoms, enhancing stool consistency, improving quality of life, and addressing psychological distress in individuals diagnosed with irritable bowel syndrome (IBS), as compared to those who receive no intervention.


Description:

Irritable bowel syndrome (IBS) is a condition linked to disturbances in the gut-brain axis and dysbiosis. Although probiotic modulation of dysbiosis appears promising for IBS treatment, identifying the specific beneficial strains remains uncertain. Furthermore, even with an effective probiotic strain, variations in efficacy among populations are observed due to environmental heterogeneity, particularly dietary influences. This study seeks to provide efficacy insights into Skal Pro powder 2g (containing Lactobacillus plantarum 299v 1x10^10 colony forming unit (CFU) and GOS), shedding light on the unique mechanisms of LP299V within the Malaysian population through a randomized controlled trial (RCT).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date March 30, 2025
Est. primary completion date November 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - IBS diagnosed using the Rome IV criteria - Age above 18 years old and any gender - Any subtypes of IBS (diarrhea, constipation or mixed) Exclusion Criteria: - Presence of red flag symptoms (weight loss, anemia, night symptoms, abdominal mass, strong family history of cancer) - Was prescribed antibiotic (s) within the past one month - Medical conditions that contraindicate probiotic use including severe sepsis and pregnancy - Presence of bowel malignancy - Diagnosis of bowel infection within the past one month - Previous abdominal surgeries - Patients with overt psychiatric illnesses including schizophrenia and manic disorders - A history of allergy to probiotic - Was prescribed probiotic (s) within the past one month - Was previously prescribed probiotic Skal Pro™ (LP299V™)

Study Design


Intervention

Combination Product:
Skal Pro
One sachet Skal Pro per day containing Lactobacillus plantarum 299v 1x10^10 CFU and GOS
Other:
Placebo
One sachet per day identical in shape, size, colour, packaging and taste to the Skal Pro sachet

Locations

Country Name City State
Malaysia Hospital Universiti Sains Malaysia Kubang Kerian Kelantan

Sponsors (1)

Lead Sponsor Collaborator
EP Plus Group Sdn Bhd

Country where clinical trial is conducted

Malaysia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Improving the severity of symptoms in individuals with IBS, assessed by IBS Symptom Severity Scale (IBSSSS) IBSSS questionnaire contains five questions that measures, on a 100-point visual analogue scale (VAS), the severity of abdominal pain, the frequency of abdominal pain, the severity of abdominal distension, dissatisfaction with bowel habits, and interference with quality of life (QOL). All five components contribute to the scores equally, yielding a theoretically range of 0 - 500, with a higher score indicating worse condition. The Malay version questionnaire will be used. Assessed at baseline, Week 1, Week 2, and Week 4.
Secondary Change in stool consistency (Bristol Stool Scale), assessed by daily stool diary Daily diary of stool consistency of each bowel movement based on Bristol Stool Scale (Type 1-7), from type 1-2 = separate hard lump stool, type 3-4= ideal stool, type 5-7 =loose stool Assessed daily from baseline to Week 4.
Secondary Change in stool frequency and satisfaction after passing stool, assessed by daily stool diary Daily diary of number of bowel movements. Assessed daily from baseline to Week 4.
Secondary Change in abdominal bloating, assessed by Bloating Severity Questionnaire (BSQ) Originally developed by Thiwan et al., this research group then translated and validated the BSQ in the Malay language (BSQ-M) [13]. There are 2 sub-scales, the 6-item Sev-Gen (Severity-General) and 5-item Sev-24 (Severity-24 hour) with responses in seven-point Likert scale on different degree of severity (from 1 = never to 7=always). For this study, only the Sev-Gen will be used. Assessed at baseline, Week 1, Week 2, and Week 4.
Secondary Improvement in Quality of Life, assessed by EQ-5D-5L Questionnaire The 5-level EQ-5D version (EQ-5D-5L) was introduced by the EuroQol Group in 2009, and consist of 2 sections, 1) the EQ-5D descriptive system and 2) the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain or discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health the participant can imagine' and 'The worst health the participant can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement. The Malay version questionnaire will be used. Assessed at baseline, Week 1, Week 2, and Week 4.
Secondary Change in Visceral Sensitivity Index The Visceral Sensitivity Index (VSI) is a 15-item questionnaire which measures gastrointestinal symptom-specific anxiety. Replies to each item are provided on a 6-point scale from "strongly disagree" (scored as 0) to "strongly agree" (scored as 5). A Malay version of the questionnaire was developed using standard forward-back translation procedures. The Malay version questionnaire will be used. Assessed at baseline, Week 1, Week 2, and Week 4.
Secondary Assessment of psychological dysfunction suing Catastrophizing Questionnaire The Coping Strategies Questionnaire (CSQ) - Catastrophizing (CAT) subscale consists of six questions on a 6-point Likert scale, with response options ranging from 0 (never) to 5 (very frequently). The Malay version questionnaire will be used. Assessed at baseline, Week 1, Week 2, and Week 4.
See also
  Status Clinical Trial Phase
Completed NCT03720314 - Microbiota Profiling in IBS
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT05213910 - Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains N/A
Recruiting NCT05985018 - Traditional Dietary Advice Vs. Mediterranean Diet in IBS N/A
Completed NCT04486469 - Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study. N/A
Completed NCT06407609 - Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS N/A
Completed NCT04656730 - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas Phase 4
Completed NCT04145856 - Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico Phase 4
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Active, not recruiting NCT03586622 - One Year Home Monitoring and Treatment of IBS Patients N/A
Completed NCT05207618 - Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant N/A
Not yet recruiting NCT06369753 - Visible Abdominal Distension N/A
Not yet recruiting NCT05157867 - In Vivo Effects of Amylase Trypsin Inhibitors N/A
Not yet recruiting NCT05100719 - The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) N/A
Recruiting NCT05001997 - Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome N/A
Recruiting NCT02953171 - Probiotics in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT03266068 - Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
Completed NCT02977975 - Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3
Completed NCT02980406 - The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level N/A